Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Sep 24:2013:636927.
doi: 10.1155/2013/636927.

Risk of cancer in diabetes: the effect of metformin

Mojtaba Malek  1 , Rokhsareh Aghili, Zahra Emami, Mohammad E Khamseh
Affiliations
Review

Risk of cancer in diabetes: the effect of metformin

Mojtaba Malek et al. ISRN Endocrinol. .

Abstract

Cancer is the second cause of death. Association of diabetes as a growing and costly disease with cancer is a major health concern. Meanwhile, preexisting diabetes is associated with an increased risk of all-cause and cancer-specific mortalities. Presence of diabetes related comorbidities, poorer response to cancer treatment, and excess mortality related to diabetes are among the most important explanations. Although diabetes appear to be a risk factor for cancer and is associated with the mortality risk in cancer patients, several factors such as diabetes duration, multiple drug therapy, and the presence of diabetes comorbidities make the assessment of the effect of diabetes treatment on cancer risk and mortality difficult. Metformin is the drug of choice for the treatment of type 2 diabetes. The available evidence from basic science, clinical, and population-based research supports the anticancer effect of metformin. However, randomized controlled clinical trials do not provide enough evidence for a strong protective effect of metformin on cancer incidence or mortality. One of the most important limitations of these trials is the short duration of the followup. Further long-term randomized controlled clinical trials specifically designed to determine metformin effect on cancer risk are needed to provide the best answer to this challenge.

PubMed Disclaimer

Figures

Figure 1
Figure 1
The role of AMPK* at cellular level.
Figure 2
Figure 2
Energy sensing pathways converge on the coactivator TORC2.
See this image and copyright information in PMC

References

    1. Ko C, Chaudhry S. The need for a multidisciplinary approach to cancer care. Journal of Surgical Research. 2002;105(1):53–57. - PubMed
    1. Noto H, Tsujimoto T, Sasazuki T, Noda M. Significantly increased risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. Endocrine Practice. 2011;17(4):616–628. - PubMed
    1. Deng L, Gui Z, Zhao L, Wang J, Shen L. Diabetes mellitus and the incidence of colorectal cancer: an updated systematic review and meta-analysis. Digestive Diseases and Sciences. 2012;57(6):1576–1585. - PubMed
    1. Jiang Y, Ben Q, Shen H, Lu W, Zhang Y, Zhu J. Diabetes mellitus and incidence and mortality of colorectal cancer: a systematic review and meta-analysis of cohort studies. European Journal of Epidemiology. 2011;26(11):863–876. - PubMed
    1. Krämer HU, Schöttker B, Raum E, Brenner H. Type 2 diabetes mellitus and colorectal cancer: meta-analysis on sex-specific differences. European Journal of Cancer. 2012;48:1269–1282. - PubMed

LinkOut - more resources